Seller record · Telehealth service

Vaylen

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 4 of 8 criteria. S2, prescription gating: The program page and its answers say the buyer pays first and answers the health questionnaire after checkout, with a full refund if a clinician declines, and the terms say payment reserves the program and starts the clinical review. 3 more criteria also fail; see the table below.

At a glance

VaylenTelehealth service

4/8criteria passed

Price: Semaglutide from $83.25 a month on a prepaid 12-month program, standard monthly plan $224
Sells: compounded semaglutide injection, compounded tirzepatide injection, and 1 more
FDA letters: None on file

Visit Vaylen See all eight dispositions

Telehealth service. Passes 4 of 8 criteria. Recorded against Standard v1.1.

A telehealth platform selling compounded semaglutide and tirzepatide injections and a daily semaglutide tablet on prepaid and monthly plans, with clinicians from OpenLoop Health. Its own pages say payment is taken before the health questionnaire, and neither a filling pharmacy nor a business address is printed.

Operating entity Vaylen Health

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Vaylen's sign-up site; Vaylen's terms on its sign-up site; Vaylen's website
S2	Prescription gating	FAIL	Vaylen's sign-up site; Vaylen's terms on its sign-up site; Vaylen's refund policy on its sign-up site
S3	Pharmacy identification	FAIL	Vaylen's sign-up site; Vaylen's terms on its sign-up site
S4	Compounding disclosure	PASS	Vaylen's website; Vaylen's sign-up site
S5	Analytical documentation	FAIL	Vaylen's website; Vaylen's sign-up site; Vaylen's terms on its sign-up site
S6	Business address	FAIL	Vaylen's website; Vaylen's terms on its sign-up site; Vaylen's privacy page on its sign-up site; Vaylen's refund policy on its sign-up site
S7	Price disclosure	PASS	Vaylen's sign-up site; Vaylen's website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed, board certified US clinician from the OpenLoop Health network reviews every case within 24 hours and decides whether to prescribe, and the program page names a medical director. The terms say every prescribing decision is made independently by the clinician.Source: Vaylen's sign-up site; Vaylen's terms on its sign-up site; Vaylen's website.

S2FAILThe program page and its answers say the buyer pays first and answers the health questionnaire after checkout, with a full refund if a clinician declines, and the terms say payment reserves the program and starts the clinical review.Source: Vaylen's sign-up site; Vaylen's terms on its sign-up site; Vaylen's refund policy on its sign-up site.

S3FAILNo filling pharmacy is named. The footer and the terms say only that prescriptions are filled by US-licensed compounding pharmacies whose name appears on the prescription label.Source: Vaylen's sign-up site; Vaylen's terms on its sign-up site.

S4PASSThe footer of the home page and of the program page states that compounded medications are not FDA-approved finished products and have not been evaluated by the FDA, and the answers repeat it beside the program's statement that the active ingredient matches the brand drugs.Source: Vaylen's website; Vaylen's sign-up site.

S5FAILNo certificate of analysis or lot document is published on the home page, the program page, the terms or the privacy policy.Source: Vaylen's website; Vaylen's sign-up site; Vaylen's terms on its sign-up site.

S6FAILNo business address appears on the home page, the program page, the terms, the privacy policy, the refund policy or the telehealth consent; the only contact printed is an email address. The terms name only applicable US law.Source: Vaylen's website; Vaylen's terms on its sign-up site; Vaylen's privacy page on its sign-up site; Vaylen's refund policy on its sign-up site.

S7PASSCompounded semaglutide injection at $83.25 a month on a 12-month program billed upfront at $999, against a standard monthly plan of $224, which a banner presents as a limited offer that was $224. Tirzepatide injection from $149 a month and the semaglutide tablet from $99 a month, each on a 12-month program billed upfront. The home page also prints a first month from $99, with no later price beside it.Source: Vaylen's sign-up site; Vaylen's website.

S8PASSNo FDA warning letter names Vaylen or Vaylen Health, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide injection, compounded tirzepatide injection, compounded semaglutide tablet.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit Vaylen

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.